Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830] (Annals of Oncology (2019) 30(11) (1821–1830), (S0923753420325904))

K. L. Jhaveri, X. V. Wang, V. Makker, S. W. Luoh, E. P. Mitchell, J. A. Zwiebel, E. Sharon, R. J. Gray, S. Li, L. M. McShane, L. V. Rubinstein, D. Patton, P. M. Williams, S. R. Hamilton, B. A. Conley, C. L. Arteaga, L. N. Harris, P. J. O'Dwyer, A. P. Chen, K. T. Flaherty

    Research output: Contribution to journalComment/debatepeer-review

    Abstract

    The authors regret that Dr Arteaga's disclosures were not complete in the original publication. Dr Arteaga's full disclosure should read as follows: CLA: grant support: Pfizer, Lilly, Radius, PUMA Biotechnology, Bayer, Takeda, Symphogen; honoraria: advisory board/steering committee: Daiichi Sankyo, ABBVIE, Novartis, Lilly, Sanofi, Radius, Taiho Oncology, PUMA Biotechnology, Merck, H3Biomedicine, Symphogen, OrigiMed, Immunomedics, Petra Pharma, G1 Therapeutics, Athenex, Dr Arteaga receives compensation for his role in the Scientific Advisory Board of the Komen Foundation, unrelated to this work; stock options: Provista, Y-TRAP. LNH: patents, royalties, other intellectual property—Philips Healthcare. The authors would like to apologise for any inconvenience caused.

    Original languageEnglish (US)
    Pages (from-to)1068
    Number of pages1
    JournalAnnals of Oncology
    Volume32
    Issue number8
    DOIs
    StatePublished - Aug 2021

    ASJC Scopus subject areas

    • Hematology
    • Oncology

    Fingerprint

    Dive into the research topics of 'Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830] (Annals of Oncology (2019) 30(11) (1821–1830), (S0923753420325904))'. Together they form a unique fingerprint.

    Cite this